Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) said the drug registration application for an additional indication of Luvometinib Tablets was approved by China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
Shares of the pharmaceutical company were down nearly 2% in Tuesday afternoon trading.
The approved indication is for the treatment of pediatric patients aged two years and older with relapsed or refractory Langerhans cell histiocytosis.
The drug was developed by Shanghai Fosun Pharmaceutical Industrial Development, a unit of Fosun Pharmaceutical.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments